NY-FRAME.IO
11.2.2021 20:32:07 CET | Business Wire | Press release
Frame.io , the world’s leading cloud-based video review and approval platform, today announced Frame.io Camera to Cloud (C2C) , a secure camera-to-cloud workflow that lets customers instantly upload and stream images from on-set cameras to creative post-production teams anywhere in the world. Frame.io C2C represents the largest change in film, television, news and commercial production workflows since the advent of digital filmmaking.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005854/en/
Customers can view the launch event on demand at the Frame.io website and sign up for the beta today. Frame.io C2C will be available this spring to all customers at no additional cost. Download the Frame.io C2C press kit here .
Frame.io C2C provides two unique services. First, C2C enables instant proxy uploads the moment cameras stop rolling so editorial can begin within seconds of calling “cut.” In addition, Frame.io C2C can live stream footage to an authorized user’s device on or off set, allowing customers to watch production as it’s happening. This is ideal for productions working during COVID, as it greatly reduces the number of people needed on set. Frame.io C2C lets editorial and other traditionally linear parts of the creative process happen in parallel while footage is still being shot.
Getting footage from a camera into post-production is a time-consuming process that requires backing up files, transferring them to a hard drive, and shipping them to another facility. Frame.io C2C eliminates that, letting customers simultaneously view a live stream of footage as it is being shot, while automatically capturing and uploading proxies as soon as the camera stops rolling.
The camera-to-cloud workflow requires a Frame.io C2C-certified device connected to compatible cameras from Arri, RED and Sony. Once authenticated, certified devices such as the Teradek CUBE 655 and Sound Devices 888 or Scorpio recorders will record, encode, and send timecode-accurate H.264 proxy files with matching filename metadata directly to Frame.io via an encrypted and secure connection using LTE, 5G or WiFi. This allows for near real-time delivery of editable proxy files to a producer, dailies facility, or editor anywhere in the world.
“Frame.io C2C is disruptive technology that changes the traditionally linear filmmaking process, allowing both on-set production and remote post-production teams to work together at the same time,” said Michael Cioni, Global SVP of Innovation at Frame.io. “This level of collaboration brings creative teams together and allows them to work faster and more collaboratively than ever before.”
In addition, Frame.io users with proper authentication credentials can view a live stream of footage while it's being shot from the comfort of their computer, iPhone, or iPad—whether they are on set or halfway around the world. This lets collaborators instantly share ideas to help bring their creative vision to life, while everyone who needs to track production progress can stay informed.
“In today’s socially distanced world—where remote work has become the norm and the number of people on-set is limited—Frame.io C2C is a game changer,” said Emery Wells, CEO of Frame.io. “Camera to Cloud gives film, television, and commercial productions a seamless new way for creative teams to do their best work, no matter where they are.”
Frame.io C2C features best-in-class security with full TPN and SOC 2 Type 2 compliance. Created by the MPAA and CDSA, TPN is the global, industry-wide initiative that defines requirements and best practices for protecting content. Combined with rigorous access controls, Frame.io C2C is an incredibly safe way to share media with authorized viewers and collaborators.
Also introduced today, the new Frame.io Cloud Devices API and C2C certification program enables hardware and software manufacturers to create their own C2C compatible products. Frame.io C2C is launching with three groundbreaking partner integrations from Teradek, Sound Devices, and Colorfront, making it compatible with more than a dozen professional camera systems from RED, Arri, and Sony.
Manufacturers interested in building Frame.io C2C Certified software and hardware can find details at developer.frame.io .
PRICING AND AVAILABILITY
C2C features are included at no additional charge for customers with a paid Frame.io account. Flexible, new monthly enterprise plans let customers and studios purchase the service they need for the duration of their production.
Frame.io C2C is currently in beta and will ship this spring. Customers can apply to participate in the beta program at the Frame.io website. Live streaming features will be available later in 2021.
FRAME.IO C2C LAUNCH PARTNERS
Teradek designs and manufactures high-performance video solutions for broadcast and cinema. A Frame.io authenticated CUBE 655 encoder delivers live streams and camera proxy files directly into Frame.io.
Sound Devices designs and manufactures the world’s leading production sound field recorders. The latest 888 and Scorpio recorders capture and transmit original audio files directly into Frame.io.
Colorfront has developed the world’s first fully cloud dailies platform. Their Express Dailies integration with Frame.io allows labs to instantly access the video and audio assets to create dailies.
ABOUT FRAME.IO
Frame.io is the world’s leading video review and approval platform with over 1 million users. Integrated with most major professional video tools, Frame.io streamlines the creative process by centralizing assets and feedback in the cloud. This allows remote creative teams to collaborate securely and in real time from anywhere in the world.
Conceived and designed in 2015 by video creators Emery Wells and John Traver, Frame.io is intuitive and simple, yet powerful enough for creative professionals, technical administrators, and clients to use with little (or no) training. Frame.io accelerates workflows and eliminates obstacles to creativity. From script or storyboard to dailies through delivery, Frame.io has reinvented the modern video workflow.
Frame.io is backed by industry heavyweights including Insight Partners, FirstMark Capital, and Accel Partners. To learn more please visit http://frame.io .
Watch: Frame.io C2C announcement
Download: Frame.io C2C Press Kit
Watch: What is Frame.io?
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005854/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom